Navigating the murky waters of the Hatch-Waxman ‘safe harbour’
Safe harbour provisions can be relied on but their boundaries are still being defined, explain Jeanna Wacker and Tasha Francis Gerasimow of Kirkland & Ellis.
- The increasing relevance of ‘technical character’ 16-08-2022
- CMA costs case improves access to justice 30-06-2022
- Gilenya injunction bid: big pharma takeaways 21-06-2022
- Solving the PCT Priority problem 14-04-2022
- When alliances fail, is arbitration the answer? 24-02-2022
Latest big pharma news
Tribal business settles Stanford opioid treatment clash
29-11-2022
Dispute centred on patented data to treat opioid addiction | Tribe said it had shared confidential data to develop a cure | Stanford University.
Amarin appeals ‘skinny label’ loss
23-11-2022
